指南与共识骨软组织肉瘤与黑色素瘤支持与姑息治疗

欧洲浸润性皮肤鳞状细胞癌跨学科共识指南:第2部分治疗更新2026

European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma: Part 2. Treatment - update 2026.
指南 / 共识 · Eur J Cancer · 2026-05-06

该指南由EADO、EDF、ESTRO、UEMS皮肤性病科和EORTC多学科专家组制定,更新了免疫功能正常及免疫抑制的浸润性皮肤鳞状细胞癌(CSCC)治疗推荐。常见原发CSCC一线为手术切除(术后切缘评估或显微控制手术),非手术候选者可考虑放疗;晚期无法治愈者一线为抗PD-1治疗,cemiplimab为EMA批准药物。

要点

  • 常见原发CSCC一线治疗为手术切除并评估切缘,切缘阴性是关键。
  • 不适合手术或放疗的晚期CSCC,一线系统治疗为抗PD-1药物。
  • 所有晚期CSCC及高危术后辅助cemiplimab决策需多学科讨论。

核心结论

  • 常见原发CSCC首选手术切除并确保切缘阴性,非手术候选者可考虑放疗。
  • 晚期或局部晚期不适合治愈性手术或放疗者,抗PD-1药物为一线系统治疗,cemiplimab为EMA批准药物。
  • 高危患者术后辅助cemiplimab及所有晚期CSCC治疗决策需多学科讨论,并考虑毒性、年龄、衰弱及合并症。

研究设计与样本

  • 由EADO、EDF、ESTRO、UEMS皮肤性病科和EORTC多学科专家组制定,基于当前文献和专家共识更新2023版指南。

主要发现

  • 常见原发CSCC一线治疗为手术切除联合术后切缘评估或显微控制手术,实现组织学切缘阴性是关键。
  • 不适合手术的候选者或肿瘤应考虑放疗。
  • 宏观区域淋巴结转移者应在多学科肿瘤委员会讨论个体化治疗。
  • 晚期CSCC二线系统治疗包括临床试验、EGFR抑制剂(西妥昔单抗)联合抗PD-1免疫治疗、化疗或放疗。

关键数值与推荐

  • cemiplimab为EMA批准的晚期CSCC系统治疗药物。
  • 高危复发CSCC术后及放疗后辅助cemiplimab决策需多学科讨论。
  • 随访频率和检查取决于潜在风险特征。

临床怎么用

  • 对可手术CSCC确保切缘阴性,非手术候选者考虑放疗。
  • 晚期CSCC一线使用抗PD-1药物,所有晚期病例需多学科讨论。
  • 高危患者术后辅助cemiplimab需多学科评估,并考虑毒性、年龄、衰弱及合并症。
  • 参与知情共享决策,并提供最佳支持治疗以改善症状管理和生活质量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Part 2 of the guideline addresses the updates on treatment recommendations in immunocompetent as well as immunosuppressed patients with invasive cutaneous squamous cell carcinoma (CSCC), based on current literature and expert consensus. A multidisciplinary panel of experts from the European Association of Dermato-Oncology (EADO), the European Dermatology Forum (EDF), the European Society for Radiotherapy and Oncology (ESTRO), the European Union of Medical Specialists (UEMS)-Dermatology Venereology and the European Organization of Research and Treatment of Cancer (EORTC), was formed to update the previous guideline on CSCC (version 2023). For common primary CSCC, first-line treatment is surgical excision with post-operative margin assessment or micrographically controlled surgery. Achieving clear histological margins is key for patients with CSCC amenable to surgery. Radiotherapy should be considered for non-surgical candidates/tumors. For patients with macroscopic regional lymph node metastases, individualized treatment should be discussed in the multidisciplinary tumor board. For patients with metastatic or locally advanced CSCC who are not candidates for curative surgery or radiotherapy, anti-PD-1 agents are the first-line systemic treatment, with cemiplimab being the approved systemic agent for advanced CSCC by the EMA. Second-line systemic treatments for advanced CSCC, include clinical trials, EGFR inhibitors (cetuximab) combined with anti-PD-1 immunotherapy, or chemotherapy or radiotherapy. The decision for adjuvant cemiplimab for CSCC at high risk of recurrence after surgery and radiotherapy should be discussed in the multidisciplinary tumor board. In addition, multidisciplinary board decisions are mandatory for all patients with advanced CSCC, considering the risks of toxicity, the age and frailty of patients and co-morbidities, including immunosuppression. Patients should be engaged in informed, shared decision-making on management and be provided with best supportive care to improve symptom management and quality of life. Frequency of follow-up visits and investigations for subsequent new CSCC depend on underlying risk characteristics.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Stratigos AJ, Dessinioti C, Garbe C, et al. European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma: Part 2. Treatment - update 2026. Eur J Cancer. 2026. PMID: 42263355. doi:10.1016/j.ejca.2026.116764

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。